Cipla to Acquire Inzpera  for INR 110.65 Cr to Bolster Paediatric & Wellness Portfolio

The transaction underlines the company’s goal to build scale in the paediatric and wellness market by combining Inzpera’s specialized portfolio with its own operational infrastructure and distribution network.

Major Pharma Giant Cipla has announced the acquisition of Inzpera Healthsciences for around INR R 110.65 crore.

Established in 2016, Inzpera Healthsciences focuses on differentiated pharmaceutical products and wellness solutions with a strong presence in the paediatric market. The company recorded a turnover of INR. 26.75 crore in the fiscal year 2024-25.

The enterprise value for Inzpera has been estimated at around INR 120 crore, with final purchase consideration after working-capital adjustments pegged at ₹110.65 crore.

Cipla, in a stock-exchange filing, disclosed that it has entered into definitive agreements to acquire a 100 per cent stake in paediatric and wellness products company Inzpera Healthsciences. The transaction, valued at approximately INR 110.65 crore, will result in Inzpera becoming a wholly owned subsidiary of Cipla upon completion.

The transaction underlines the company’s goal to build scale in the paediatric and wellness market by combining Inzpera’s specialised portfolio with its own operational infrastructure and distribution network.

According to the company, the acquisition is “a strategic move aimed at combining Inzpera’s differentiated portfolio of paediatric pharmaceutical and wellness products with Cipla’s strong distribution network and operational capabilities to drive growth and scalability.”

Reportedly, the deal is an all-cash transaction and is expected to be closed within one month.

Stay tuned for more such updates on Digital Health News